(MNMD) Mind Medicine - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: CA60255C8850
MM120, MM402, Anxiety, ADHD, Autism
Description: MNMD Mind Medicine October 23, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a clinical-stage biopharma focused on novel therapeutics for brain-health disorders. Its lead pipeline consists of MM120, a compound currently in Phase 3 trials for generalized anxiety disorder (GAD) and attention-deficit/hyperactivity disorder (ADHD), and MM402, the R-enantiomer of MDMA, which is in Phase I testing for core symptoms of autism spectrum disorder (ASD). The company is headquartered in New York, NY, and trades as a common-stock biotechnology firm.
Recent data points that may influence MindMed’s valuation include: (1) a cash runway of roughly $75 million as of the latest 10-Q, giving the firm ~12 months of operating liquidity at its current burn rate of $6-7 million per quarter; (2) a market-cap of about $200 million, reflecting a price-to-sales multiple of ~15× on projected 2025 revenues from MM120, assuming successful Phase 3 outcomes; and (3) sector-wide growth, with the global anxiety-treatment market projected to expand at a CAGR of ~5 % through 2030, providing a favorable demand backdrop for MM120 if approved.
For a deeper, data-driven look at how these factors translate into risk-adjusted upside, you might explore MindMed’s profile on ValueRay to see the latest analyst models and scenario analyses.
MNMD Stock Overview
| Market Cap in USD | 979m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-03-03 |
MNMD Stock Ratings
| Growth Rating | 56.8% |
| Fundamental | 26.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 93.4% |
| Analyst Rating | 4.64 of 5 |
MNMD Dividends
Currently no dividends paidMNMD Growth Ratios
| Growth Correlation 3m | 69.6% |
| Growth Correlation 12m | 58.3% |
| Growth Correlation 5y | -53.3% |
| CAGR 5y | 75.69% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.30 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.93 |
| Sharpe Ratio 12m | 0.94 |
| Alpha | 68.04 |
| Beta | 3.312 |
| Volatility | 68.32% |
| Current Volume | 5325.7k |
| Average Volume 20d | 1695.3k |
| Stop Loss | 13.2 (-7%) |
| Signal | 1.13 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.38 (>2.0%) and ΔFCFTA -11.18pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 (>3.0%) and CFO -101.6m > Net Income -114.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (85.3m) change vs 12m ago 18.68% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 1.80%; Δ -1.80pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.24 (EBITDA TTM -110.2m / Interest Expense TTM 4.32m) >= 6 (WARN >= 3) |
Altman Z'' -9.54
| (A) 0.57 = (Total Current Assets 189.1m - Total Current Liabilities 38.0m) / Total Assets 265.1m |
| (B) -1.75 = Retained Earnings (Balance) -465.0m / Total Assets 265.1m |
| warn (B) unusual magnitude: -1.75 — check mapping/units |
| (C) -0.21 = EBIT TTM -57.3m / Avg Total Assets 266.6m |
| (D) -5.82 = Book Value of Equity -464.2m / Total Liabilities 79.7m |
| Total Rating: -9.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.68
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -12.13% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.22 = 2.48 |
| 5. Debt/Ebitda -0.07 = -2.50 |
| 6. ROIC - WACC (= -35.38)% = -12.50 |
| 7. RoE -50.24% = -2.50 |
| 8. Rev. Trend -4.37% = -0.33 |
| 9. EPS Trend 30.57% = 1.53 |
What is the price of MNMD shares?
As of November 03, 2025, the stock is trading at USD 14.20 with a total of 5,325,688 shares traded.
Over the past week, the price has changed by +10.68%, over one month by +16.20%, over three months by +51.71% and over the past year by +134.32%.
Over the past week, the price has changed by +10.68%, over one month by +16.20%, over three months by +51.71% and over the past year by +134.32%.
Is Mind Medicine a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, Mind Medicine (NASDAQ:MNMD) is currently (November 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 26.68 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MNMD is around 10.06 USD . This means that MNMD is currently overvalued and has a potential downside of -29.15%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MNMD is around 10.06 USD . This means that MNMD is currently overvalued and has a potential downside of -29.15%.
Is MNMD a buy, sell or hold?
Mind Medicine has received a consensus analysts rating of 4.64.
Therefore, it is recommended to buy MNMD.
- Strong Buy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MNMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.9 | 75.4% |
| Analysts Target Price | 24.9 | 75.4% |
| ValueRay Target Price | 12.1 | -14.9% |
MNMD Fundamental Data Overview October 30, 2025
Market Cap USD = 979.3m (979.3m USD * 1.0 USD.USD)
P/B = 5.0151
Beta = 3.312
Revenue TTM = 0.0 USD
EBIT TTM = -57.3m USD
EBITDA TTM = -110.2m USD
Long Term Debt = 41.2m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 41.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.80m USD (from netDebt column, last quarter)
Enterprise Value = 837.4m USD (979.3m + Debt 41.2m - CCE 183.0m)
Interest Coverage Ratio = -13.24 (Ebit TTM -57.3m / Interest Expense TTM 4.32m)
FCF Yield = -12.13% (FCF TTM -101.6m / Enterprise Value 837.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 130.3m) / Revenue TTM)
Tobins Q-Ratio = 3.16 (Enterprise Value 837.4m / Total Assets 265.1m)
Interest Expense / Debt = 5.68% (Interest Expense 2.34m / Debt 41.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.2m (EBIT -57.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.98 (Total Current Assets 189.1m / Total Current Liabilities 38.0m)
Debt / Equity = 0.22 (Debt 41.2m / totalStockholderEquity, last quarter 185.4m)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 7.80m / EBITDA -110.2m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 7.80m / FCF TTM -101.6m)
Total Stockholder Equity = 228.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.20% (Net Income -114.5m / Total Assets 265.1m)
RoE = -50.24% (Net Income TTM -114.5m / Total Stockholder Equity 228.0m)
RoCE = -21.27% (EBIT -57.3m / Capital Employed (Equity 228.0m + L.T.Debt 41.2m))
RoIC = -17.72% (negative operating profit) (NOPAT -45.2m / Invested Capital 255.3m)
WACC = 17.67% (E(979.3m)/V(1.02b) * Re(18.22%) + D(41.2m)/V(1.02b) * Rd(5.68%) * (1-Tc(0.21)))
Discount Rate = 18.22% (= CAPM, Blume Beta Adj.) -> capped to 17.95%
Shares Correlation 3-Years: 100.0 | Cagr: 45.56%
Fair Price DCF = unknown (Cash Flow -101.6m)
EPS Correlation: 30.57 | EPS CAGR: 5.43% | SUE: 1.50 | # QB: 1
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
P/B = 5.0151
Beta = 3.312
Revenue TTM = 0.0 USD
EBIT TTM = -57.3m USD
EBITDA TTM = -110.2m USD
Long Term Debt = 41.2m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 41.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.80m USD (from netDebt column, last quarter)
Enterprise Value = 837.4m USD (979.3m + Debt 41.2m - CCE 183.0m)
Interest Coverage Ratio = -13.24 (Ebit TTM -57.3m / Interest Expense TTM 4.32m)
FCF Yield = -12.13% (FCF TTM -101.6m / Enterprise Value 837.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 130.3m) / Revenue TTM)
Tobins Q-Ratio = 3.16 (Enterprise Value 837.4m / Total Assets 265.1m)
Interest Expense / Debt = 5.68% (Interest Expense 2.34m / Debt 41.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.2m (EBIT -57.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.98 (Total Current Assets 189.1m / Total Current Liabilities 38.0m)
Debt / Equity = 0.22 (Debt 41.2m / totalStockholderEquity, last quarter 185.4m)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 7.80m / EBITDA -110.2m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 7.80m / FCF TTM -101.6m)
Total Stockholder Equity = 228.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.20% (Net Income -114.5m / Total Assets 265.1m)
RoE = -50.24% (Net Income TTM -114.5m / Total Stockholder Equity 228.0m)
RoCE = -21.27% (EBIT -57.3m / Capital Employed (Equity 228.0m + L.T.Debt 41.2m))
RoIC = -17.72% (negative operating profit) (NOPAT -45.2m / Invested Capital 255.3m)
WACC = 17.67% (E(979.3m)/V(1.02b) * Re(18.22%) + D(41.2m)/V(1.02b) * Rd(5.68%) * (1-Tc(0.21)))
Discount Rate = 18.22% (= CAPM, Blume Beta Adj.) -> capped to 17.95%
Shares Correlation 3-Years: 100.0 | Cagr: 45.56%
Fair Price DCF = unknown (Cash Flow -101.6m)
EPS Correlation: 30.57 | EPS CAGR: 5.43% | SUE: 1.50 | # QB: 1
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for MNMD Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle